Log In
Print this Print this


Also known as: Orzel, tegafur/uracil

  Manage Alerts
Collapse Summary General Information
Company Otsuka Pharmaceutical Co. Ltd.
DescriptionCombination therapy of tegafur plus uracil
Molecular Target Thymidylate synthetase (TYMS)
Mechanism of ActionThymidylate synthase inhibitor
Therapeutic ModalitySmall molecule: Combination
Latest Stage of DevelopmentMarketed
Standard IndicationColorectal cancer
Indication DetailsTreat first-line metastatic colorectal cancer (mCRC)
Regulatory Designation
PartnerMerck KGaA

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today